TdC 273: Diagnóstico de Mieloma múltiplo

🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨Pedro Magno, Iago Jorge e Gabriel Cunha discutem os principais conceitos sobre manifestações clínicas e diagnóstico de mieloma múltiplo.Quer saber mais sobre amiloidose, veja o tópico: https://www.tadeclinicagem.com.br/guia/321/amiloidose-manifestacoes-clinicas-e-diagnostico/Minutagem:00:10 Apresentação 03:55 Definição05:40 Epidemiologia07:45 Como o paciente chega 08:00 Mnemônicos 09:00 Cálcio11:50 Rim - disfunção renal17:05 Anemia19:50 Bone - osso21:45 Outros sintomas além do CRAB26: 45 Apresentação do paciente27:00 Caso 127:45 Caso 228:30 Investigação35:55 Retornando aos casos38:30 Diagnóstico 43:10 Retornando aos casos44:00 Doenças e manifestações atípicas do mieloma52:00 EncerramentoReferências:1. Rajkumar, S Vincent. “Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.” American journal of hematology vol. 99,9 (2024): 1802-1824. doi:10.1002/ajh.274222. Kumar, Shaji K et al. “Multiple myeloma.” Nature reviews. Disease primers vol. 3 17046. 20 Jul. 2017, doi:10.1038/nrdp.2017.463. Rajkumar, S Vincent et al. “International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.” The Lancet. Oncology vol. 15,12 (2014): e538-48. doi:10.1016/S1470-2045(14)70442-54. Dimopoulos, Meletios A et al. “Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.” The Lancet. Oncology vol. 24,7 (2023): e293-e311. doi:10.1016/S1470-2045(23)00223-15. Palumbo, Antonio, and Kenneth Anderson. “Multiple myeloma.” The New England journal of medicine vol. 364,11 (2011): 1046-60. doi:10.1056/NEJMra10114426. Nandra, Taran K et al. “Multiple myeloma: what a non-haematologist should know.” Clinical medicine (London, England) vol. 22,3 (2022): 230-233. doi:10.7861/clinmed.2022-01447. Sive, Jonathan et al. “Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline.” British journal of haematology vol. 193,2 (2021): 245-268. doi:10.1111/bjh.174108. Mikhael, Joseph et al. “Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncologyvol. 37,14 (2019): 1228-1263. doi:10.1200/JCO.18.020969. Marron, Thomas U et al. “Validation and Utility of the Free Light Chain Assay in Pleural Effusions of Patients With Multiple Myeloma.” Clinical lymphoma, myeloma & leukemia vol. 16,7 (2016): e113-7. doi:10.1016/j.clml.2016.04.00810. Witzig, T E et al. “Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma.” Cancer vol. 72,1 (1993): 108-13. doi:10.1002/1097-0142(19930701)72:1<108::aid-cncr2820720121>3.0.co;2-t11. Dimopoulos, M A et al. “Pathogenesis and treatment of renal failure in multiple myeloma.” Leukemia vol. 22,8 (2008): 1485-93. doi:10.1038/leu.2008.13112. Agbuduwe, Charles et al. “Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK.” Clinical medicine (London, England) vol. 20,5 (2020): e191-e195. doi:10.7861/clinmed.2019-048813. Leung, Nelson et al. “Monoclonal Gammopathy of Renal Significance.” The New England journal of medicine vol. 384,20 (2021): 1931-1941. doi:10.1056/NEJMra1810907